Komai-Koma, M., Li, D., Wang, E., Vaughan, D. and Xu, D. (2014) Anti-Toll-like receptor 2 and 4 antibodies suppress inflammatory response in mice. Immunology, 143(3), pp. 354-362. (doi: 10.1111/imm.12312)
Full text not currently available from Enlighten.
Abstract
Toll-like receptors (TLRs) 2 and 4 recognize different endogenous and exogenous agonists and play a distinct role in infection and inflammation. However, their ultimate effect in a given infectious and inflammatory disease is less understood. We produced polyclonal anti-murine TLR2 and TLR4 antibodies and investigated their effect on cutaneous leishmaniasis and inflammatory arthritis. Administration of these antibodies to susceptible BALB/c mice, infected in the footpad with Leishmania major, reduced footpad swelling but not the parasite load compared with mice treated with control IgG. The antibodies synergistically reduced leishmanial-specific T-cell proliferation, T helper type 1 and type 2 cytokine production, specific IgG1 and IgG2a antibody synthesis, and T-cell receptor and co-stimulatory molecule expression on dendritic cells in infected mice. We then tested the effect of these antibodies on collagen-induced arthritis (CIA) in DBA/1 mice, a classic model of chronic inflammation. Both antibodies markedly suppressed the development of clinical parameters with concomitant reduction of pro-inflammatory cytokine production. These data therefore suggest that anti-TLR2 and 4 antibodies may have a synergistic therapeutic effect on inflammatory disease in vivo.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Xu, Dr Damo and Komai-Koma, Dr Mousa and Vaughan, Ms Diane |
Authors: | Komai-Koma, M., Li, D., Wang, E., Vaughan, D., and Xu, D. |
College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
Journal Name: | Immunology |
Publisher: | Wiley-Blackwell Publishing Ltd. |
ISSN: | 0019-2805 |
ISSN (Online): | 1365-2567 |
University Staff: Request a correction | Enlighten Editors: Update this record